Welireg Delays Kidney Cancer Progression, Betters Quality of Life
Welireg outperformed Afinitor in time to disease progression and patient-reported quality of life in the treatment of metastatic clear cell renal cell carcinoma.
Read More
Adcetris Improves Lymphoma Outcomes, Regardless of PET Scan Results
While PET scans have been used to predict Hodgkin lymphoma outcomes, adding Adcetris to frontline therapy improved outcomes for patients, regardless of their results.
Lenvima May Prolong Survival in Advanced Liver Cancer That Progressed on Immunotherapy
Patients with advanced HCC who progressed after treatment with immunotherapy may have a survival benefit when treated with second-line Lenvima.
Majority of Patients with Mesothelioma Subtype Responded to Keytruda-Lenvima Combo
Patients with malignant pleural mesothelioma tended to have prolonged benefit when treated with Keytruda plus Lenvima in the PEMMELA clinical trial.
Tibsovo Plus Vidaza Is Beneficial for Patients With IDH1-Mutant Acute Myeloid Leukemia
Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial.
Post-Treatment Venclexta Improves Outcomes and Is Well-Tolerated in CLL
Regardless of whether it was guided by minimal residual disease status or given at a fixed dosage, consolidation Venclexta proved to be beneficial in patients with chronic lymphocytic leukemia.
